文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

四例 BRCA1 和 BRCA2 基因突变的双重杂合性病例:临床、病理和家族特征。

Four new cases of double heterozygosity for BRCA1 and BRCA2 gene mutations: clinical, pathological, and family characteristics.

机构信息

Unit of Medical Oncology and Hematology, Istituto Clinico Humanitas, Via Manzoni 56, 20089 Rozzano, Milan, Italy.

出版信息

Breast Cancer Res Treat. 2010 Nov;124(1):251-8. doi: 10.1007/s10549-010-0853-8. Epub 2010 Apr 7.


DOI:10.1007/s10549-010-0853-8
PMID:20373018
Abstract

Double heterozygosity (DH) for BRCA1 and BRCA2 mutations is a very rare finding, particularly in non-Ashkenazi individuals, and only a few cases have been reported to date. In addition, little is known on the pathological features of the tumors that occur in DH cases and on their family history of cancer. Four carriers of pathogenic mutations in both BRCA1 and BRCA2 were identified among women who underwent genetic counseling for hereditary susceptibility to breast and ovarian carcinoma at three different Italian institutions. Clinical, pathological, and family history data were collected from medical records and during genetic counseling sessions. All identified DH cases developed breast carcinoma and three of them were also diagnosed with ovarian carcinoma. Mean ages of breast and ovarian cancer diagnosis were 42.7 and 48.6 years, respectively. The majority of breast cancers showed a BRCA1-related phenotype, being negative for hormone receptors and HER2. Two cases reported different gastrointestinal tumors among relatives. Although the individuals described in this study show more severe clinical features in comparison to previously reported BRCA1 and BRCA2 DH cases, our observations support the hypothesis of a non specific phenotype of DH cases in terms of age of disease onset. In addition, our observations indicate that in DH patients breast carcinogenesis appears to be driven mainly by the mutations in BRCA1. The possible association of DH for BRCA gene mutations with gastrointestinal tumors is in keeping with previous reports, but needs to be confirmed by further analyses.

摘要

BRCA1 和 BRCA2 基因突变的双杂合性(DH)是一种非常罕见的发现,特别是在非阿什肯纳兹人个体中,迄今为止仅报道了少数病例。此外,对于 DH 病例中发生的肿瘤的病理特征及其癌症家族史知之甚少。在意大利的三个不同机构,对遗传性乳腺癌和卵巢癌易感性进行遗传咨询的女性中,鉴定出了四个同时携带 BRCA1 和 BRCA2 致病性突变的携带者。从病历和遗传咨询期间收集了临床、病理和家族史数据。所有鉴定出的 DH 病例均发生了乳腺癌,其中 3 例还被诊断为卵巢癌。乳腺癌和卵巢癌的平均诊断年龄分别为 42.7 岁和 48.6 岁。大多数乳腺癌表现出 BRCA1 相关表型,对激素受体和 HER2 呈阴性。有两例报告了亲属中不同的胃肠道肿瘤。尽管本研究中描述的个体与以前报道的 BRCA1 和 BRCA2 DH 病例相比表现出更严重的临床特征,但我们的观察结果支持 DH 病例在发病年龄方面具有非特异性表型的假设。此外,我们的观察结果表明,在 DH 患者中,乳腺癌的发生似乎主要由 BRCA1 中的突变驱动。DH 与 BRCA 基因突变相关的胃肠道肿瘤的可能关联与以前的报告一致,但需要进一步分析来证实。

相似文献

[1]
Four new cases of double heterozygosity for BRCA1 and BRCA2 gene mutations: clinical, pathological, and family characteristics.

Breast Cancer Res Treat. 2010-4-7

[2]
Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.

Clin Cancer Res. 2002-12

[3]
Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families.

Breast Cancer Res Treat. 2010-3-11

[4]
Maternal and paternal lineage double heterozygosity alteration in familial breast cancer: a first case report.

Breast Cancer Res Treat. 2010-8-21

[5]
Analysis of breast cancer susceptibility genes BRCA1 and BRCA2 in Thai familial and isolated early-onset breast and ovarian cancer.

Hum Mutat. 2002-9

[6]
Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.

Breast Cancer Res Treat. 2010-3-4

[7]
Novel BRCA1/2 mutations in Serbian breast and breast-ovarian cancer patients with hereditary predisposition.

Cancer Genet Cytogenet. 2010-10-1

[8]
BRCA1 and BRCA2 mutations in Turkish breast/ovarian families and young breast cancer patients.

Br J Cancer. 2000-9

[9]
Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.

Cancer. 2006-12-15

[10]
Phenocopy breast cancer rates in Israeli BRCA1 BRCA2 mutation carrier families: is the risk increased in non-carriers?

Breast Cancer Res Treat. 2011-11-24

引用本文的文献

[1]
Clinicopathological features of Chinese ovarian cancer patients with double heterozygosity for cancer-predisposed genes.

BMC Cancer. 2025-8-28

[2]
Case Report: Clinical impact of and vs. and germline double heterozygosity in ovarian cancer: a comparative case study.

Front Oncol. 2025-7-24

[3]
Double heterozygosity for and in breast cancer: considerations in surveillance and cancer risk management.

BMJ Case Rep. 2025-4-22

[4]
Double Heterozygosity for Germline Mutations in Chinese Breast Cancer Patients.

Cancers (Basel). 2024-7-15

[5]
Characteristics of Chinese breast cancer patients with double heterozygosity for BRCA1 and BRCA2 germline pathogenic variants.

Breast Cancer Res Treat. 2024-11

[6]
[Not Available].

Med Genet. 2022-5-7

[7]
Metastatic breast cancer with double heterozygosity for the and genes responding to olaparib: A case report.

Oncol Lett. 2024-4-9

[8]
How does re-classification of variants of unknown significance (VUS) impact the management of patients at risk for hereditary breast cancer?

BMC Med Genomics. 2022-5-31

[9]
A Case of Triple-Negative Breast Cancer with Germline Pathogenic Variants in Both and .

Case Rep Oncol. 2021-11-18

[10]
Five Italian Families with Two Mutations in Genes.

Genes (Basel). 2020-12-3

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索